Cancer-associated thrombosis (including venous thromboembolism (VTE) and arterial
events) is highly consequential for patients with cancer and is associated with worsened …

Thrombosis, both venous and arterial, is a leading cause of morbidity and mortality in
patients with cancer. Studies on the molecular basis of cancer-associated thrombophilia …

In cancer patients, thrombocytopenia can result from bone marrow infiltration or from
anticancer medications and represents an important limitation for the use of antithrombotic …

Venous thromboembolism (VTE) is common in patients with cancer. Although in the general
population blood type non-O is associated with increased VTE risk, the impact of ABO blood …

Cardio-oncology has grown rapidly worldwide as an emerging interdisciplinary discipline
over the past decade. In the present bibliometric review, we employed VOSviewer and …

Abstract Background Risk assessment models (RAMs) are relevant approaches to identify
cancer outpatients at high risk of venous thromboembolism (VTE). Among the proposed …

Venous thromboembolism (VTE) is a major cause of both morbidity and mortality in patients
with cancer. Venous thromboembolism, which includes both deep vein thrombosis and …

Patients with cancer have an increased risk of venous-and arterial thromboembolism
(VTE/ATE). Anti-cancer treatments including surgery, radiotherapy, and certain …

Opinion statement Prophylaxis and treatment of thrombosis in leukemic patients still
represent a major challenge with several clinical questions yet to be solved. Indeed, the …

Patients with pancreatic cancer have a very high risk of both venous and arterial thrombosis
compared with other cancers, caused by a tumour-driven hypercoagulable state. Better …